Agenus to Host “The Road Taken” R&D Event on November 12, 2022
05 Oktober 2022 - 2:30PM
Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive
pipeline of therapeutics designed to activate the immune response
to cancers and infections, today announced it will host an
in-person and virtual Research & Development event (“The Road
Taken”) on Saturday, November 12, 2022, from 2:00 p.m. to 5:00 p.m.
ET at the Prudential Tower in Boston, MA.
The Road Taken will feature both key opinion leaders at the
forefront of immunotherapy development for cancer and Agenus’
expanding leadership team. During the event, speakers will
highlight recent developments within the Agenus clinical-stage
pipeline of novel immunotherapy programs, study details involving
botensilimab, a multi-functional Fc-enhanced anti-CTLA-4 which
activates innate and adaptive immune responses, opportunities to
combine Agenus pipeline assets to overcome immuno-oncology
resistance and strategies to reach commercialization as rapidly as
possible.
Featured speakers will include:
- Michael Atkins, MD, Deputy Director
& Professor, Acting Chief, Division of Hematology/Oncology
MedStar Georgetown University Hospital; SITC 2022 Lifetime
Achievement Award Recipient
- Breelyn Wilky, MD, Director of
Sarcoma Medical Oncology, Deputy Associate Director for Clinical
Research University of Colorado Medicine; Principal
Investigator/Presenter C-800 Study
- Steven O’Day, MD, Chief Medical
Officer, Agenus
- Joseph Grossman, MD, VP and Head of
Exploratory Medicines, Agenus
- Patricia Carlos, Chief Regulatory,
Quality, and Safety Officer, Agenus
The scientific program will take place from 2:00 p.m. to 4:00
p.m. ET and will be followed by a reception from 4:00 p.m. to 5:00
p.m. ET.
The event will be webcast live and institutional investors and
research analysts are invited to attend in person. Individuals
interested in attending the event in person should contact Agenus
Investor Relations at investorrelations@agenus.com. The webcast
will be available on the Investors section of the Agenus website at
investor.agenusbio.com. To register for the webcast, please click
here. Following the webcast, an archived version will be available
on the Agenus website.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on
the discovery and development of therapies that engage the body's
immune system to fight cancer and infections. The Company's vision
is to expand the patient populations benefiting from cancer
immunotherapy by pursuing combination approaches that leverage a
broad repertoire of antibody therapeutics, adoptive cell therapies
(through its subsidiary MiNK Therapeutics), and adjuvants (through
its subsidiary SaponiQx). The Company is equipped with a suite of
antibody discovery platforms and a state-of-the-art GMP
manufacturing facility with the capacity to support clinical
programs. Agenus is headquartered in Lexington, MA. For more
information, please visit www.agenusbio.com and our Twitter handle
@agenus_bio. Information that may be important to investors will be
routinely posted on our website and Twitter.
Forward-Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements relating to our technologies,
therapeutic candidates, and capabilities, for instance, statements
regarding therapeutic benefit and efficacy, mechanism of action,
potency, durability, and safety and tolerability profile of our
therapeutic candidates, both alone and in combination with each
other and/or other agents; statements regarding future plans,
including research, clinical, regulatory, and commercialization
plans; and any other statements containing the words "may,"
"believes," "expects," "anticipates," "hopes," "intends," "plans,"
"will" and similar expressions are intended to identify
forward-looking statements. These forward-looking statements are
subject to risks and uncertainties that could cause actual results
to differ materially. These risks and uncertainties include, among
others, the factors described under the Risk Factors section of our
most recent Quarterly Report on Form 10-Q or Annual Report on Form
10-K filed with the Securities and Exchange Commission and
available on our website: www.agenusbio.com. Agenus cautions
investors not to place considerable reliance on the forward-looking
statements contained in this release. These statements speak only
as of the date of this press release, and Agenus undertakes no
obligation to update or revise the statements, other than to the
extent required by law. All forward-looking statements are
expressly qualified in their entirety by this cautionary
statement.
Contact
Ethan Lovell
Chief External Affairs & Communications Officer
339-927-1763
ethan.lovell@agenusbio.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
Von Apr 2023 bis Apr 2024